Did You Know...
...that after Parker Brothers executives turned down the game of Monopoly because it had "52 fundamental errors" (including taking too long to play), a copy of the game wound up in the home of the company president who stayed up until 1 a.m. to finish playing it? He was so impressed by the game that the next day he wrote to inventor Charles Darrow and offered to buy it!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8030486 | Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation The present invention provides with a process of preparing an optically active succinimide derivative, which is a key intermediate for production of ranirestat. A compound (3) is easily prepared by treating the derivative of succinic acid diester of the formula (2):... | 10/04/2011 |
| 7482449 | Process for making spirolactone compounds This invention relates to a process for making spirolactone compounds analogous to formula I. ... | 01/27/2009 |
| 7419969 | HIV integrase inhibitors: cyclic pyrimidinone compounds The invention encompasses a series of pyrimidinone compounds which inhibit HIV integrase and thereby prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses intermediates us... | 09/02/2008 |
| 7384929 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryl or heteroaryl azaspiroalkene/alkane compounds, prodrugs or metabolites of these compounds, or pharmaceutically acceptab... | 06/10/2008 |
| 7368569 | Process for making spirolactone compounds This invention relates to a process for making spirolactone compounds analogous to formula I ... | 05/06/2008 |
| 7345047 | Substituted [1,2,3]triazolo[4,5-d]pyrimidines The invention provides novel substituted cyclopentane compounds (in particular, substituted [1,2,3]triazolo[4,5-d]pyrimidines), their use as medicaments (in particular, their use as anti-thrombotic agents), compositions containing them and processes for their prepar... | 03/18/2008 |
| 7319102 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors The present invention relates to 2,6,7-substituted pyrrolo[2,3-d]pyrimidines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates... | 01/15/2008 |
| 7304081 | Amido compounds and their use as pharmaceuticals The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases... | 12/04/2007 |
| 7273859 | HIV integrase inhibitors: cyclic pyrimidinone compounds The invention encompasses a series of pyrimidinone compounds which inhibit HIV integrase and thereby prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses intermediates us... | 09/25/2007 |
| 7268133 | Cannabinoid receptor ligands and uses thereof Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein ... | 09/11/2007 |
| 7262195 | Compounds useful as motilin agonists and method Compounds are provided which are useful in treating disorders of gastrointestinal motility and which have the structure or a pharmaceutically acceptable salt thereof, a prodrug ester thereof, and all stereoisomer... | 08/28/2007 |
| 7262187 | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor The present invention relates to azolopyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which c... | 08/28/2007 |
| 7262186 | Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor The present invention relates to azolopyriniidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which ... | 08/28/2007 |
| 7232823 | Cannabinoid receptor ligands and uses thereof Compounds of Formula (I) or (II) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein ... | 06/19/2007 |
| 7202251 | Bicyclic anilide spirohydantoin CGRP receptor antagonists The present invention is directed to compounds of the formula: that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache... | 04/10/2007 |
| 7192949 | Substituted bicyclic pyrimidinones as a mitotic kinesin KSP inhibitors The present invention relates to cycloalkylpyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions wh... | 03/20/2007 |
| 7189722 | Aryl spirohydantoin CGRP receptor antagonists The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pha... | 03/13/2007 |
| 7176210 | Cannabinoid receptor ligands and uses thereof Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein ... | 02/13/2007 |
| 7135476 | Spiro tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists Compounds of the formula (I): and pharmaceutically acceptable salts or prodrugs thereof, wherein m, n, R1, R2, R3, R4, R5, R6, R7, R | 11/14/2006 |
| 7129239 | Purine compounds and uses thereof Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. ... | 10/31/2006 |
| 7125996 | Fluorescent probes for use in protein kinase inhibitor binding assay The invention provides methods relating to a novel screening assay format that can be applied to broad members of the protein kinase gene family. The assay uses a series of labeled, active site probes described herein that can be displaced by an inhibitor agent. The... | 10/24/2006 |
| 7122662 | Tricyclic compound having spiro union This invention relates to tricyclic compounds having spiro union represented by the following formula (I) or its salt which is useful as a drug, and in particular, as an inhibitor for activated blood coagulation factor X, which can be administered orally and which e... | 10/17/2006 |
| 7105526 | Benzimidazole derivatives The present invention relates to novel benzimidazole derivatives which are useful as neuropeptide Y receptor antagonists. ... | 09/12/2006 |
| 7098330 | Pyrazolylamine substituted quinazoline compounds useful as protein kinase inhibitors This invention describes novel pyrazole compounds of formula III: wherein Ring D is a 5–7 membered monocyclic ring or 8–10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R... | 08/29/2006 |
| 7091345 | Amino-substituted dihydropyrimido[4,5-D]pyrimidinone derivatives Compounds of formula I are described. These compounds are protein kinase inhibitors, in particular they inhibit the src family tyrosine kinases. Thus, these compounds are useful for the treatment of diseases medi... | 08/15/2006 |
| 7067655 | Adenosine A2a receptor antagonists Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, cycloalkenyl, or heteroaryl; X is alkylene or —C(O)CH2 | 06/27/2006 |
| 7018840 | Fluorescent metal sensors, and methods of making and using the same The present invention is directed, in part, to fluorescent metal sensors for detecting metal ions, and methods of making and using the same. ... | 03/28/2006 |
| 7014925 | Heterogeneous spiro compounds in organic light emitting device elements A family of non-polymeric heterogeneous spiro compounds having visible light emissive, hole-transport, electron transport or bipolar-transport properties may be used in organic light emitting devices (OLEDs), as an emissive layer in the OLEDs and/or in one or more o... | 03/21/2006 |
| 6969719 | Polycyclic guanine phosphodiesterase V inhibitors A polycyclic guanine phosphodiesterase V inhibitor having the formula (I.1) or (II.1), with the variables defined herein, which is useful for treating sexual dysfunction and other physiological disorders: A representativ... | 11/29/2005 |
| 6933296 | Compounds effective as β2-adrenoreceptor agonists as well as PDE4-inhibitors The compounds of formula I in which Ar1, A, R6, R7, R8 and Ar2 have the meanings as given in the description are novel effective bronchial therapeutics ... | 08/23/2005 |
| 6916555 | Organic luminescence device In an organic luminescence device formed of one or plural layers of organic films between an anode and a cathode, at least one layer is any one of a luminescence layer, an electron injection layer and an electron-transporting layer and is formed of at least a spiro ... | 07/12/2005 |
| 6916926 | Process for the preparation of (±) 1-3-dioxolanes and the optical resolution thereof (±) 3-(4-Phenyl-1-piperazinyl)-1,2-propanediol cyclic acetals, a process for the optical resolution thereof and their use as intermediates for the preparation of (−) 3-(4-phenyl-1-piperazinyl)-1,2-propanediol (levodropropizine) and salts thereof are described her... | 07/12/2005 |
| 6914064 | 1,4-Disubstituted piperazine derivatives useful as uro-selective α1-adrenoceptor blockers The present invention relates to a novel 1,4-disubstituted piperazine derivatives of Formula I, and their pharmaceutically acceptable acid addition salts having excellent uro-selective α1-adrenoceptor antag... | 07/05/2005 |
| 6911463 | 3-substituted oxindole β-3 agonists The present invention relates to a β3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity. ... | 06/28/2005 |
| 6894005 | Herbicides Compounds of formula wherein the substituents have the meanings given in claim 1, and agronomically tolerable salts, isomers and enantiomer of those compounds, are suitable for use as herbicides. ... | 05/17/2005 |
| 6890921 | Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia This invention relates to a series of arylsubstituted piperazines, of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibi... | 05/10/2005 |
| 6878718 | Phenylalanine enamide derivatives Phenylalanine enamide derivatives of formula (1) are described: wherein R1 is a group Ar1L2Ar2Alk- in which: Ar1 | 04/12/2005 |
| 6872719 | Phenylalanine enamide derivatives Phenylalanine enamide derivatives of formula (1) are described: wherein R1 is a —CH3, —(CH2)3CH3, —CH2CH2OH, —CH2CH2 | 03/29/2005 |
| 6849634 | Potassium channel inhibitors Compounds useful as potassium channel inhibitors and especially useful for the treatment of cardiac arrhythmias and cell proliferative disorders are described. ... | 02/01/2005 |
| 6844348 | 2,3,4-cyclopentan-2,3,4-triol-1-yl compounds The invention provides a compound of formula (I): wherein R1 is alkyl C1-6 or alkenyl C2-6, both independently optionally substituted by one or more groups selected from alkyl C1-5... | 01/18/2005 |
